Pilar Garrido Gutiérrez

Pilar Garrido Gutiérrez María Pilar Garrido Gutiérrez (born 15 April 1966) is a Spanish jurist, university professor, and politician. She served as General Coordinator of Podemos Euskadi from 2020 to 2024. She previously served as a member of the Congress of Deputies representing Gipuzkoa for the Unidas Podemos coalition (2019–2023) and as a Senator for Podemos (2015–2019). Provided by Wikipedia
Showing 1 - 8 results of 8 for search 'Pilar Garrido', query time: 0.02s Refine Results
  1. 1
    Tratamiento de disfunción protésica aórtica transcatéter mediante explante e implante de nueva prótesis aórtica transcatéter in situ

    Tratamiento de disfunción protésica aórtica transcatéter mediante explante e implante de nueva prótesis aórtica transcatéter in situ by Pilar Garrido-Martín, José R. González-Rodríguez, Nora García-Borges, Javier Montoto-López, Rafael Martínez-Sanz

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Management of Intracranial Metastases in EGFR-Mutated NSCLC: A Review of Literature following an Unusual Case Report

    Management of Intracranial Metastases in EGFR-Mutated NSCLC: A Review of Literature following an Unusual Case Report by Víctor Albarrán, Javier Pozas, Juan José Soto, Jorge Esteban, Elena Corral, Yolanda Lage, Pablo Gajate, Pilar Garrido

    Published 2021-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: a position statement of SEOM, SEAP and SEFH

    Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: a position statement of SEOM, SEAP and SEFH by Ruth Vera, José Palacios, Xavier Matías-Guiu, Miguel Martín, María Jesús Lamas, Enrique de Álava, Miguel Ángel Calleja, Azucena Aldaz, Pilar Garrido

    Published 2017-11-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Optical genome mapping reveals complex cytogenetic abnormalities in multiple myeloma

    Optical genome mapping reveals complex cytogenetic abnormalities in multiple myeloma by Jorge A. Palacios, Mónica Bernal, Jose R. Vílchez, Pilar Garrido, Pilar Jiménez, Juan F. Gutiérrez-Bautista, María C. Barrera-Aguilera, Lucía Ballesta, Teresa Rodríguez, María J. Olivares-Durán, Francisco Ruiz-Cabello

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology

    Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology by Irene Carretero-Barrio, Lara Pijuan, Adrián Illarramendi, Daniel Curto, Fernando López-Ríos, Ángel Estébanez-Gallo, Josep Castellvi, Sofía Granados-Aparici, Desamparados Compañ-Quilis, Rosa Noguera, Isabel Esteban-Rodríguez, Ignacio Sánchez-Güerri, Ana Delia Ramos-Guerra, Juan Enrique Ortuño, Pilar Garrido, María Jesús Ledesma-Carbayo, Amparo Benito, José Palacios

    Published 2024-10-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in RET Fusion-Positive NSCLC

    Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in RET Fusion-Positive NSCLC by Caicun Zhou, MD, PhD, Silvia Novello, MD, PhD, Pilar Garrido, MD, PhD, Christophe Dooms, MD, PhD, Jorge Alatorre-Alexander, MD, Niels Reinmuth, MD, Gill Worthy, PhD, Kim Cocks, PhD, Justin Williams, PhD, Hongmei Han, MS, MApSt, Minji K. Uh, PhD, Nalin Payakachat, PhD, Adrienne M. Gilligan, PhD, Koichi Goto, MD, PhD

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study)

    Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study) by Miguel García-Pardo, Marta García de Herreros, Edouard Auclin, Miquel Ferriol-Galmes, Juan Carlos Laguna, Teresa Gorría, Gerard Caravaca, Joan Sart, Víctor Albarrán-Artahona, Rafael López-Castro, Cristina Teixidó, Giancarlo Castellano, Alex Martínez Bedmar, Ainara Arcocha, Laura Alcolea, Manuel Jiménez, Mario Bernabeu, David Delgado-Cano, Alejandro Navarro, Aleix Prat, Noemí Reguart, Javier Elio, Pilar Garrido, Natasha B. Leighl, Benjamin Besse, Laura Mezquita

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC

    CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC by Jay M. Lee, MD, Jean-Louis Pujol, MD, PhD, Jun Zhang, MD, PhD, Oleg Leonov, MD, PhD, Masahiro Tsuboi, MD, PhD, Edward S. Kim, MD, MBA, Calvin Ng, MD, Nicolas Moreno-Mata, MD, PhD, Amy Cummings, MD, PhD, Ilhan Hacibekiroglu, MD, Abidin Sehitogullari, MD, Nirmal Veeramachaneni, MD, Cathy Spillane, PhD, Jiawei Duan, PhD, Claudia Bossen, PhD, Alexander Savchenko, MD, PhD, Chiara Lobetti-Bodoni, MD, PhD, Tony Mok, MD, Pilar Garrido, MD

    Published 2025-08-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: